These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2004258)

  • 21. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease.
    Laihinen A; Rinne UK; Suchy I
    Acta Neurol Scand; 1992 Dec; 86(6):593-5. PubMed ID: 1481646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy].
    Rinne UK
    Nervenarzt; 1999 Jan; 70 Suppl 1():S19-25. PubMed ID: 10087526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic effect of lisuride in advanced Parkinson's disease.
    Meneghetti G; Bracco F; Giometto B; Ferla S; Schergna E
    Eur Neurol; 1986; 25(1):74-80. PubMed ID: 3510126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Orally administered lisuride in the treatment of complex fluctuations of motion in Parkinson disease].
    Luquín MR; Obeso JA; Vaamonde J; Martínez Lage JM
    Neurologia; 1989 Sep; 4(7):229-32. PubMed ID: 2638588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of lisuride in severe Parkinson's disease.
    Chin D; Yu YL; Huang CY
    Clin Exp Neurol; 1986; 22():63-9. PubMed ID: 3581512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The dopamine agonist, lisuride, in the therapy of Parkinson disease].
    Madeja UD
    Acta Histochem Suppl; 1992; 42():25-31. PubMed ID: 1584973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
    Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A
    Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonist effect of terguride in Parkinson's disease.
    Ruggieri S; Stocchi F; Baronti F; Viselli F; Horowski R; Lucarelli C; Agnoli A
    Clin Neuropharmacol; 1991 Oct; 14(5):450-6. PubMed ID: 1683813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease.
    Capria A; Attanasio A; Quatrana M; Cannata D; Fioravanti M; Stocchi F; Ruggieri S
    Clin Neuropharmacol; 1989 Aug; 12(4):331-8. PubMed ID: 2804995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 37. Further studies with lisuride in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E
    Eur Neurol; 1983; 22(2):119-23. PubMed ID: 6341071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lisuride in Parkinson's disease. 4-year follow-up.
    Giovannini P; Scigliano G; Piccolo I; Soliveri P; Suchy I; Caraceni T
    Clin Neuropharmacol; 1988 Jun; 11(3):201-11. PubMed ID: 3401856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisuride combined with levodopa in advanced Parkinson disease.
    Lieberman AN; Goldstein M; Leibowitz M; Neophytides A; Gopinathan G; Walker R; Pact V
    Neurology; 1981 Nov; 31(11):1466-9. PubMed ID: 7031504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.